Literature DB >> 9048987

Apolipoprotein E allele frequencies in patients with late-onset sporadic Alzheimer's dementia in Hungary.

J Kálmán1, A Juhász, A Császár, A Kanka, E Maglóczky, K Bencsik, Z Janka, I Raskó.   

Abstract

INTRODUCTION: The presence of the apolipoprotein E4 allele (apoE4) has been recognized as a risk factor for the development of presenile and senile forms of Alzheimer's dementia (AD).
MATERIAL AND METHODS: The apoE alleles frequency of 71 normal controls (NC), 60 demented controls (DC) and 50 senile type AD subjects was determined by polymerase chain reaction in order to get data about the apoE polymorphism of the Hungarian AD population.
RESULTS: The apoE3/3 genotype was the most common in all groups. The apoE4 frequency was significantly higher (28%) in the AD group than that was (7% and 9%) in the NC and DC populations, respectively. No apoE4 homozygotes were found in the DC group and the number of heterozygotes was lower in the DC than in the AD group.
CONCLUSION: The results are in good agreement with others in the literature and support the occurrence of an increased apoE4 allele frequency in Hungarian senile AD population.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9048987     DOI: 10.1111/j.1600-0404.1997.tb00069.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  2 in total

1.  CYP46 T/C polymorphism is not associated with Alzheimer's dementia in a population from Hungary.

Authors:  Anna Juhász; Agnes Rimanóczy; Krisztina Boda; Gábor Vincze; Gyozo Szlávik; Marianna Zana; Annamária Bjelik; Magdolna Pákáski; Nikoletta Bódi; András Palotás; Zoltán Janka; János Kálmán
Journal:  Neurochem Res       Date:  2005-08       Impact factor: 3.996

2.  ApoE -491A/T promoter polymorphism is not an independent risk factor, but associated with the epsilon4 allele in Hungarian Alzheimer's dementia population.

Authors:  Anna Juhász; András Palotás; Zoltán Janka; Agnes Rimanóczy; Miklós Palotás; Nikoletta Bódi; Krisztina Boda; Marianna Zana; Gábor Vincze; János Kálmán
Journal:  Neurochem Res       Date:  2005-05       Impact factor: 3.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.